CS MEDICA A/S: US trademark registration approval for CANNASEN®
CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today that the United States Patent and Trademark Office has approved CS MEDICA’s trademark CANNASEN®, registration no. 6,624,142.
The trademark approval of CANNASEN® is an important step in CS MEDICA's market strategy to expand sales of its product line CANNASEN® in the US market. The trademark registration no. for CANNASEN® is 6,624,142 and is valid until November 19, 2028.
“The validation of CANNASEN® being officially confirmed as a trademark in the US is of key importance for our strategy going forward in the North American market.” says CEO Lone Henriksen.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.
Tags: